Open, Single Centre, Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for De Novo Renal Transplant Recipients Followed by Randomisation to Calcineurin Inhibitor Containing or Calcineurin Inhibitor Free Immunosuppression
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Allograft function
研究概览
简要总结
The main purpose of this study is to investigate, whether a steroid free immunosuppressive treatment is a valuable alternative in the treatment of de novo kidney transplant recipients and if it is possible to withdraw calcineurin inhibitors after 3 months.
详细描述
Protocol synopsis Title An open, single centre, pilot study to investigate a steroid free immunosuppressive regimen for de novo renal transplant recipients followed by a two arm randomization to a calcineurin inhibitor containing and a calcineurin inhibitor free maintenance immunosuppression after three months. Study code Sterfree pilot study Project phase An open, single centre, one arm study followed by a 1:1 randomized, parallel group, comparative study after three months. Study objectives To obtain preliminary information on the efficacy and safety of a rapamycin / sodium-mycophenolate (Myfortic) / tacrolimus regimen in the absence of steroids for the prevention of acute rejection following renal transplantation. To compare a low dose tacrolimus / rapamycin / sodium-mycophenolate (Myfortic) regimen to a rapamycin / sodium-mycophenolate regimen in patients without evidence of acute rejection after three months.
Efficacy:
Primary endpoint
- Plasma creatinine (and creatinine clearance (Cockcroft)) Secondary endpoints
- Incidence of first acute rejections and total number of acute rejections
- Total number of anti-rejection treatments
- Patients successfully withdrawn from calcineurin inhibitor at three months
- Graft survival
- Patient survival
Safety:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •adult patients with end stage kidney disease suitable for primary renal transplantation or retransplantation
- •patients receiving a graft from a living related, living unrelated or brain-death donor
排除标准
- •patients with a low or high immunological risk constellation
研究组 & 干预措施
A
Rapamycin - MMF after 3 months
干预措施: Rapamycin (Drug)
B
Low dose tacrolimus - MMF - Rapamycin after 3 months
干预措施: Rapamycin (Drug)
结局指标
主要结局
Allograft function
时间窗: 6 months
次要结局
- Patients successfully withdrawn from calcineurin inhibitor after three months(3 months)
- Graft survival(6 months)
- Patient survival(6 months)
